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believe that priority assessment in patients awaiting heart transplanta-
tion on the basis of QT dispersion measurements is premature.
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Reply
We appreciate the interest of Zabel and colleagues in our recent
report (1). We also agree that it is important to be clear regarding the
interpretation of our results. We would like to respond to their
comments.
1. The analysis of QT dispersion risk used two different measures of
dispersion: the maximal 2 minimal QT interval (QTDISP) and the
coefficient of variation of all QT intervals (QTCV). These variables
were highly significant (p 5 0.009 and p 5 0.001, respectively) when
analyzed as continuous variables without selection of a cutoff. The
dichotomization of patients on the basis of a cutoff for QTDISP of
140 ms and QTCV of 9% presented in our report was for illustrative
purposes only. The actual statistical model yields a continuum of risk
based on the value for QTDISP and QTCV. The significance of these
predictors remained after adjustment for other potential risk factors in
a multivariate analysis and after the removal of the 13 subjects with
atrial fibrillation. It can be seen in the original report that all analyses
consistently showed the utility of QT dispersion as a risk factor when
measured as described in the patient cohort under study (1).
Recent prospective studies (1,2) have demonstrated a significant
correlation between QT dispersion and mortality in patients with heart
failure, although some preliminary studies may suggest otherwise. It is
reasonable to assume that patients awaiting heart transplantation
represent a sicker subset of patients whose data may not be extrapo-
lated to patients with heart failure in general. We look forward to
reading the final published reports on the subject alluded to by Zabel
and colleagues (3,4).
2. The issue is raised that U waves may have contributed to an
increase in measured QT dispersion in the patients studied.
However, U waves were not included in the analysis (1) and therefore
did not contribute to increased QT dispersion in the original report.
3. In terms of electrocardiographic (ECG) analysis, the ECGs were
read by two independent observers blinded as to outcome, with the aid
of a magnifying lens, without a digitizing pad. The method for
obtaining ECGs was, as surmized, a standard 4 3 3 format. We used
this ECG format because it is currently the standard method for
obtaining ECGs and therefore most widely applicable with existing
equipment. Although transient changes in heart rate during the brief
period of acquisition could have affected QT dispersion, we doubt that
a sizable and systematic pattern would have occurred that would have
affected its measurement.
4. We considered the possibility that patients with atrial fibrillation
whose RR intervals can vary from beat to beat could have affected the
interpretation of our data. In fact, not only did we consider this
possibility, but we included specific data on this subject in the
published report (1). Although patients with atrial fibrillation were
included in most of the overall analyses, we did report specific data in
which the 13 patients with atrial fibrillation were excluded from
analysis (see Fig. 3 and the results and discussion sections). Indexes of
QT dispersion remained significant predictors of risk both before and
after the 13 subjects with atrial fibrillation were removed from the
analysis.
As ardent students of the scientific process, we hope that our work
serves as the springboard for additional studies in this area, so that we
can ultimately know how to best select patients who are still likely to
die while awaiting a donor heart.
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Echocardiography in Staphylococcus
aureus Bacteremia
Fowler et al. (1) investigated the diagnostic and prognostic usefulness
of transesophageal echocardiography (TEE) in patients with Staphy-
lococcus aureus bacteremia. The authors suggest that infective endo-
carditis is common in patients with S. aureus bacteremia and is
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associated with an increased risk of death from sepsis. They further
conclude that TEE is frequently needed to make the diagnosis of
infective endocarditis and should be considered in all patients with S.
aureus bacteremia. We agree that bacteremia is a serious condition and
is associated with morbidity and mortality, and we commend the
authors on their efforts to identify patients with infective endocarditis
among this group. However, we believe that their conclusions are not
justified on the basis of their study.
1. It is unclear exactly what hypothesis the authors were trying to
test and how they designed the study to test it. They appear to want to
evaluate the use of TEE in the diagnosis of infective endocarditis and
to demonstrate that it is better than transthoracic echocardiography
(TTE) for this purpose. This approach is problematic because the
authors used TEE as part of the reference standard (along with the
Duke criteria) for the diagnosis of infective endocarditis. They had no
way of addressing specificity, and the sensitivity of TEE is naturally
better than TTE because they considered TEE the reference standard.
Thus, their study is not appropriately designed to determine whether
TEE is better than TTE in this setting.
2. The authors evaluated only 59% of eligible patients with S.
aureus bacteremia. The remaining patients were not evaluated because
of either patient or physician refusal. Thus, their sample may not be
representative of the intended study population. Furthermore, al-
though the authors present the demographic and clinical characteris-
tics of both the study and excluded groups, they did not report any
statistical comparisons. When we made calculations based on the
present data, there appeared to be significant differences between
included and excluded patients. The proportion of patients with an
unknown source of bacteremia in each group is significantly different
(p 5 0.001), as is the proportion of patients with catheter-related sepsis
(p 5 0.001). These baseline differences are significant even after
adjustment for multiple comparisons and strengthens the premise that
their sample may not be representative of all patients with S. aureus
bacteremia. Specifically, the excluded group had a higher percentage
of unknown infection source and a lower percentage of a catheter
source. How these exclusions affect the authors’ conclusion is unclear;
however, the direction of any bias inherent in the selection of cases
should be addressed.
3. The authors analyzed multiple outcomes between subjects with
and without infective endocarditis. They claim that death due to
Staphylococcus sepsis was significantly more likely in patients with
infective endocarditis. The p value by Fisher exact test for this
comparison is 0.034. Not only is this misreported twice as 0.003 in the
report, but no mention of multiple comparisons is made. With four
outcome measures being compared, the risk of a type I error is 0.20 (if
alpha is 0.05). Using the Bonferroni correction, the alpha value for a
significant difference should have been set at 0.0125. Thus, statistical
significance was not achieved. Hence, there may not be a difference
between the groups with and without infective endocarditis as far as
death due to S. aureus bacteremia.
4. No information was provided concerning the specific treatment
regimens administered during the prospective evaluation. Differences
in treatment regimen in either group would either enhance or dilute
any outcome relation.
In conclusion, the unclear hypothesis, sampling procedure, differ-
ences between included and excluded patients, statistically weak
conclusions and lack of standardized treatment protocols make it
difficult to accept the generalizability of their conclusions. We feel
that this study does not establish routine TEE in patients with S.
aureus bacteremia as the basis for future evaluation of clinical
therapies.
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Reply
We thank Guzzo and Simpson for their interest in our report and for
the questions that they raise regarding various aspects of it. We would
like to clarify several points that address these misunderstandings.
Our colleagues suggested that we were using transesophageal
echocardiographic (TEE) findings as our reference standard for the
diagnosis of endocarditis. This suggestion is incorrect. We used the
Duke criteria as the reference standard measure by which the diagno-
sis of endocarditis was made (see Table 2). This diagnostic schema is
both sensitive (1–4) and specific (1,5) for the diagnosis of endocarditis
and has been validated at Duke and elsewhere. TEE findings merely
fulfilled a portion of these diagnostic criteria, which also include
clinical and microbiologic criteria. Thus, the diagnosis of endocarditis
in our report rested upon a validated diagnostic schema.
Guzzo and Simpson suggested that the group of patients undergo-
ing TEE might not be representative of the intended study population
because excluded patients who were significantly more likely to have
no identifiable focus of infection and were significantly less likely to
have an intravascular catheter source of infection. Indeed, these facts
would make excluded patients more likely to have endocarditis, thus
supporting our findings. The absence of an identifiable focus of
infection among patients with Staphylococcus aureus bacteremia is a
powerful risk factor for endocarditis (6), and patients with an intra-
vascular device are at low risk for endocarditis when the catheter is
promptly removed (7–9). Thus, the effect of the excluded patients
would be underestimation of our findings. In other words, had fewer
patients with a nonidentifiable focus of infection been excluded, an
even higher rate of endocarditis might have occurred.
Our colleagues took issue with the statistical evidence surrounding
the mortality of patients with and without endocarditis. We acknowl-
edge that the correct p value for patients dying of S. aureus endocar-
ditis is 0.03, as we reported in the abstract section. Furthermore, as
demonstrated by the fact that our colleagues performed the calcula-
tion, we have provided the discerning reader with the means of
calculating Bonferroni corrections should it be considered necessary.
However, we interpret our finding as significant, because it makes
numerical (15.4% mortality rate among endocarditis patients versus
2.6% among patients without endocarditis) and clinical sense (patients
with endocarditis are more likely to die than patients without endo-
carditis), as well as being statistically valid.
Finally, Guzzo and Simpson suggested that differences in treatment
regimen would have an impact on patient outcome. Although we agree
1444 LETTERS TO THE EDITOR JACC Vol. 31, No. 6
May 1998:1440–8
